When his $44 billion purchase of Twitter is finalized, Elon Musk will add social-media magnate to a resume that already includes electric vehicle entrepreneur, aerospace manufacturing innovator and world’s richest person. But in seeking to preserve what he deems to be free speech and make changes related to content moderation, Musk threatens to wipe out the brand-safety guardrails that have lured wary health and pharma brands onto the platform.
Source: MMM Online
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more
